Pharmasianews.com

Jump to

Nod by international regulators key for Cadila: Dandekar

Getting an approval for the product for all the four areas i.e, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis is a big achievement for Cadila said Vikas Dandekar.
'Doubt Ranbaxy claim that Mohali product filings not hit'

The question that needs to be resolved is what exactly is happening in terms of product filing and why is Ranbaxy saying that the product filings have not been impacted, says Vikas Dandekar, India Bureau Chief, PharmAsiaNews.Com.
Ranbaxy to have 30% mkt share for Lipitor: PharmAsiaNews

Vikas Dandekar of PharmAsiaNews.com tells CNBC-TV18 that the US FDA approval for Lipitor is definitely going to be a big positive for Ranbaxy.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Pharmasianews.com

Nod by international regulators key for Cadila: Dandekar

'Doubt Ranbaxy claim that Mohali product filings not hit'

Ranbaxy to have 30% mkt share for Lipitor: PharmAsiaNews